{"id":"lidoca-ne-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reactions (rare with amide lidocaine)"},{"rate":null,"effect":"Systemic toxicity (CNS effects: tremor, seizures)"},{"rate":null,"effect":"Cardiovascular effects (hypotension, arrhythmias)"},{"rate":null,"effect":"Local reactions (burning, stinging at injection site)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lidocaine is a local anesthetic that works by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and the generation of action potentials, thereby blocking pain signal transmission along nerves. It is used topically or by injection to produce local anesthesia in specific tissues or regions.","oneSentence":"Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:11.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Local anesthesia for minor surgical procedures"},{"name":"Topical anesthesia for skin and mucous membranes"},{"name":"Infiltration anesthesia"}]},"trialDetails":[{"nctId":"NCT02597699","phase":"PHASE3","title":"Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-12-18","conditions":"Termination of Pregnancy, Feticide","enrollment":66},{"nctId":"NCT06047093","phase":"NA","title":"Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristics in Chronically HBV-infected Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-03-08","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT04650074","phase":"PHASE2, PHASE3","title":"Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2021-11-05","conditions":"Neuropathic Pain, Complex Regional Pain Syndrome Type 1","enrollment":31},{"nctId":"NCT05004519","phase":"NA","title":"Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass","status":"COMPLETED","sponsor":"matthieu clanet","startDate":"2021-10-05","conditions":"Analgesics, Opioid","enrollment":183},{"nctId":"NCT05087732","phase":"NA","title":"Effectiveness and Safety of STYLAGE® M LIDOCAINE Versus STYLAGE® M in Filling Nasolabial Folds","status":"COMPLETED","sponsor":"Laboratoires Vivacy","startDate":"2021-10-19","conditions":"Aging","enrollment":64},{"nctId":"NCT04813614","phase":"NA","title":"Effectiveness and Safety of STYLAGE® M Lidocaïne for Lips' Volume Augmentation and/or Redefinition of the Outline of the Lips (SMILE)","status":"COMPLETED","sponsor":"Laboratoires Vivacy","startDate":"2021-05-31","conditions":"Esthetics","enrollment":92},{"nctId":"NCT04844216","phase":"NA","title":"Effectiveness and Safety of STYLAGE® L Lidocaïne in the Treatment of Nasolabial Folds","status":"COMPLETED","sponsor":"Laboratoires Vivacy","startDate":"2021-04-16","conditions":"Aging","enrollment":50},{"nctId":"NCT04075578","phase":"","title":"Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-26","conditions":"Bladder, Overactive","enrollment":60},{"nctId":"NCT03317912","phase":"PHASE4","title":"Perioperative Lignocaine and Sleep Disturbance","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2017-12","conditions":"Sleep Disturbance","enrollment":40},{"nctId":"NCT01964248","phase":"PHASE3","title":"Local Anesthesia Before Arterial Puncture for Blood Gas Analysis","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2012-12","conditions":"Indication of Blood Gas Analysis by Radial Artery Blood Sampling","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1166,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lignocaïne","Linisol"],"phase":"marketed","status":"active","brandName":"Lidocaïne 2%","genericName":"Lidocaïne 2%","companyName":"University of Liege","companyId":"university-of-liege","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia for minor surgical procedures, Topical anesthesia for skin and mucous membranes, Infiltration anesthesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}